Gilead Sciences (GILD) PT Bumped to $98 at BMO Capital Posts Q2, Remains Sidelined

Jefferies Remains Sidelined on Gilead Sciences (GILD) Following 2Q - PT to $93

Jefferies maintained a Hold rating on Gilead Sciences (NASDAQ: GILD), and cut the price target to $93.00 (from $97.00) following the company's 2Q earnings report. GILD's strong bottom-line results were driven by HIVB strength, as well as buybacks. HIV sales remain strong, with particular... More

Gilead Sciences (GILD) PT Lowered to $108 at Piper Jaffray

Piper Jaffray analyst Joshua Schimmer lowered his price target on Gilead Sciences (NASDAQ: GILD) to $108.00 (from $114.00) following results and lowered guidance but maintained an Overweight rating.

Schimmer commented, "After the close, GILD reported 2Q results, lowering its revenue and raising its opex guidance... More

Gilead Sciences (GILD) PT Trimmed to $115 at Credit Suisse

Credit Suisse analyst Alethia Young lowered estimates and her price target on Gilead Sciences (NASDAQ: GILD) to $115.00 (from $120.00) following results but maintained a Outperform rating.

Young commented, "Harvoni was the focus heading into the quarter; it missed consensus and guidance was lowered (likely due to HCV). Total revenues... More

Needham & Company Downgrades Gilead Sciences (GILD) to Hold

Needham & Company downgraded Gilead Sciences (NASDAQ: GILD) from Buy to Hold.

Analyst Alan Carr commented, "Gilead reported 2Q16 financial results yesterday. Product sales of $7.65B were consistent w/ our $7.71B and consensus $7.77B expectations. WW Harvoni and Sovaldi sales were $2.56B and $1.36B... More

Gilead Sciences (GILD): Lower Revenue Guidance Highlights Concerns - Baird

Baird analyst, Brian Skorney, reiterated his Outperform rating on shares of Gilead Sciences (NASDAQ: GILD) but is incrementally more cautious after earnings. Though Hep C sales met expectations, management didn't show as much confidence in a stabilization as they have in the... More

Gilead Sciences (GILD) Tops Q2 EPS by 6c

Gilead Sciences (NASDAQ: GILD) reported Q2 EPS of $3.08, $0.06 better than the analyst estimate of $3.02. Revenue for the quarter came in at $7.78 billion versus the consensus estimate of $7.79 billion.

otal product sales for the second quarter of 2016 were $7.7 billion compared to $8.1 billion for the same period in 2015. Product sales for the second quarter of 2016 were $4.9... More